Aktis Oncology $AKTS Stock Purchased by Mirador Capital Partners LP

Mirador Capital Partners LP lifted its stake in shares of Aktis Oncology (NASDAQ:AKTS) by 232.9% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 133,558 shares of the technology company’s stock after purchasing an additional 93,434 shares during the quarter. Mirador Capital Partners LP’s holdings in Aktis Oncology were worth $2,600,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. BlackRock Inc. boosted its holdings in shares of Aktis Oncology by 7.9% during the 2nd quarter. BlackRock Inc. now owns 2,278,358 shares of the technology company’s stock valued at $73,431,000 after acquiring an additional 166,231 shares in the last quarter. Wellington Management Group LLP acquired a new position in Aktis Oncology in the 2nd quarter worth about $63,372,000. Jupiter Topco LLC bought a new position in Aktis Oncology in the second quarter valued at about $42,359,000. Alyeska Investment Group L.P. acquired a new stake in shares of Aktis Oncology during the second quarter valued at about $9,347,000. Finally, Bank of America Corp DE boosted its stake in shares of Aktis Oncology by 4.2% during the second quarter. Bank of America Corp DE now owns 72,835 shares of the technology company’s stock valued at $2,347,000 after purchasing an additional 2,909 shares in the last quarter. Institutional investors and hedge funds own 28.84% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on AKTS shares. Wedbush reaffirmed an “outperform” rating and issued a $35.00 price objective on shares of Aktis Oncology in a research note on Friday, October 2nd. JPMorgan Chase & Co. boosted their target price on shares of Aktis Oncology from $30.00 to $33.00 and gave the stock an “overweight” rating in a report on Tuesday, July 14th. BMO Capital Markets began coverage on shares of Aktis Oncology in a research report on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 price target for the company. Oppenheimer assumed coverage on shares of Aktis Oncology in a research note on Wednesday, September 9th. They set an “outperform” rating and a $40.00 price target for the company. Finally, Weiss Ratings cut shares of Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $35.62.

Aktis Oncology Price Performance

Shares of AKTS stock opened at $18.15 on Friday. The stock has a market capitalization of $975.56 million and a PE ratio of -22.13. The business’s 50 day simple moving average is $22.96 and its 200 day simple moving average is $22.12. Aktis Oncology has a one year low of $14.72 and a one year high of $34.19.

Aktis Oncology (NASDAQ:AKTS) last issued its quarterly earnings results on Thursday, August 13th. The technology company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.01). The firm had revenue of $3.38 million for the quarter, compared to analysts’ expectations of $2.70 million. As a group, research analysts expect that Aktis Oncology will post -1.85 earnings per share for the current year.

Insider Transactions at Aktis Oncology

In related news, Director Ken Herrmann sold 4,856 shares of the business’s stock in a transaction on Monday, July 20th. The shares were sold at an average price of $24.56, for a total value of $119,263.36. Following the transaction, the director owned 3,506 shares in the company, valued at $86,107.36. The trade was a 58.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.30% of the stock is currently owned by insiders.

Aktis Oncology Company Profile

Aktis Oncology, Inc is a clinical-stage biopharmaceutical company developing targeted alpha therapies for the treatment of cancer. Its research is focused on creating therapies designed to selectively deliver alpha-particle radiation to tumor cells while limiting exposure to surrounding healthy tissue.

The company’s platform uses proprietary tumor-targeting molecules, including engineered miniproteins, to bind specific targets found on cancer cells and transport radioactive payloads to tumors.